Causes of early death in multiple myeloma patients who are ineligible for high‐dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|4|E73-E74

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.4, 2015-04, pp. : E73-E74

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

High-Dose Chemotherapy with Hematopoietic Stem Cell Transplantation for Patients with Advanced Multiple Myeloma

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-07 ,pp. : 272-274

Karger

Access to resources Recommend Favorite

Outcome of patients with multiple myeloma and hypotension during high‐dose chemotherapy

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 6, 2015-06 ,pp. : E125-E127

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cyclophosphamide‐based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma

By  

JOURNAL OF CLINICAL APHERESIS, Vol. 30, Iss. 3, 2015-06 ,pp. : 176-182

John Wiley & Sons Inc

Access to resources Recommend Favorite

High-Dose Idarubicin, Busulphan and Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma Responsive to DAV Chemotherapy: Comparison with a Historical Control

By  

Acta Haematologica, Vol. 115, Iss. 1-2, 2006-01 ,pp. : 9-14

Karger

Access to resources Recommend Favorite

The Feasibility and Efficacy of Dose-Adjusted Bortezomib, Melphalan and Dexamethasone for Transplantation-Ineligible Patients with Newly Diagnosed Multiple Myeloma

By  

Acta Haematologica, Vol. 134, Iss. 4, 2015-0 ,pp. : 229-230

Karger

Access to resources Recommend Favorite